NCT05052723 2025-11-19
Cabozantinib and Pembrolizumab in Metastatic Pancreas
University of Kentucky
Phase 2 Completed
Clinical Trials
11 trialsNCT01979393 2025-08-01
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT01441947 2025-05-25
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT05007613 2025-01-01
Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
National Taiwan University Hospital
Phase 2 Completed
NCT03200587 2024-07-03
Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
University of Utah
Phase 1 Completed
NCT01466036 2024-03-05
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04205799 2023-02-13
CABOCOL-01
Centre Francois Baclesse
Phase 2 Completed
NCT01822522 2023-01-10
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
National Cancer Institute (NCI)
Phase 1 Completed
NCT01588821 2020-09-29
Cabozantinib in Advanced Solid Malignancies
Massachusetts General Hospital
Phase 2 Completed
NCT01738438 2016-12-06
Cabozantinib for Metastatic Triple Negative BrCa
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01553656 2015-08-20
Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
Exelixis
Phase 1 Completed